Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition
- 98 Downloads
While the effects of d-amphetamine in increasing performance have been established, there is a paucity of information on the effects of methamphetamine on cognition in drug-naive subjects, and no published information on the effects of intravenous methamphetamine administration in dependent individuals. The dihydropyridine-class calcium channel antagonist, isradipine, has been posited as a putative treatment to prevent methamphetamine-associated hypertensive crisis and its sequelae. Yet, isradipine’s effects on cognitive performance in methamphetamine-dependent individuals are not known.
Since individuals whose dependence on methamphetamine is attributable to the need to enhance performance may be loath to take a cognition-impairing medication, even for the treatment of life-threatening hypertensive crisis, it would be important to determine isradipine’s effects on performance.
We therefore examined in a blinded, placebo-controlled, crossover design the cognitive effects of low and high doses of intravenous methamphetamine (15 mg and 30 mg, respectively) in both the presence and absence of isradipine.
Intravenous d-methamphetamine produced dose-dependent increases in attention, concentration, and psychomotor performance. Isradipine, both with and without methamphetamine, had a modest effect to decrease attention.
Our results do not support the further testing of isradipine as a medication for improving the cognitive impairments that have been associated with chronic methamphetamine use.
KeywordsIsradipine Methamphetamine Cognition Cognitive performance Attention Concentration Perceptual-motor function Dopamine Humans
- American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington D.C.Google Scholar
- Besson JA, Palin AN, Ebmeier KP, Eagles JM (1988) Calcium antagonists and multi-infarct dementia: a trial involving sequential NMR and psychometric assessment. Int J Geriatr Psychiatry 3:99–105Google Scholar
- Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352:1347–1351CrossRefPubMedGoogle Scholar
- Gunne LM (1977) Effects of amphetamine in humans. In: Martin WR (ed) Drug addiction II: amphetamine, psychotogen, and marihuana dependence. Springer, Berlin Heidelberg New York, pp 247–275Google Scholar
- Hunt D (1995) Pulse check: national trends in drug abuse. Office of National Drug Control Policy, Washington D.C.Google Scholar
- Lepakhin VK, Ivleva AI, Romashova MF, Udotova SA, Zubovskii LG (1992) The effect of isradipine on the central and cerebral hemodynamics of patients with circulatory encephalopathy and hypertension [in Russian]. Eksp Klin Farmakol 55:24–26Google Scholar
- LeVere SD, LeVere TE (1994) Old age and cognition: evaluation of a human short-term memory test with nonhuman primates and the memory-enhancing effects of nimodipine. Psychobiology 22:106–111Google Scholar
- McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum Comput 14:463–466Google Scholar
- Quevedo J, Vianna M, Daroit D, Born AG, Kuyven CR, Roesler R, Quillfeldt JA (1998) L-type voltage-dependent calcium channel blocker nifedipine enhances memory retention when infused into the hippocampus. Neurobiol Learn Mem 69:320–325Google Scholar
- Rawson RA, McCann MJ, Hasson AJ, Ling W (2000) Addiction pharmacotherapy 2000: new options, new challenges. J Psychoact Drugs 32:371–378Google Scholar
- SAS Institute, Inc. (2002) SAS user’s guide: statistics, version 9.00. SAS Institute, Inc., Cary, NCGoogle Scholar
- Sauter A, Rudin M (1986) Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 17:1228–1234Google Scholar
- Silverstone PH, Oldman D, Johnson B, Cowen PJ (1992) Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int Clin Psychopharmacol 7:37–43Google Scholar
- Spiegel R (1979) Effects of amphetamines on performance and on polygraphic sleep parameters in man. In: Passouant P, Oswald I (eds) Pharmacology of the states of alertness. Pergamon, Oxford, pp 189–201Google Scholar
- Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Le JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028–6036Google Scholar
- US Department of Health and Human Services (2001) The DAWN report. The Substance Abuse and Mental Health Services Administration (SAMHSA), Drug Abuse Warning Network (DAWN), Washington D.C.Google Scholar
- Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377–382CrossRefPubMedGoogle Scholar